Minnetronix Neuro Launches Global Neurapheresis™ Consortium
Collaborative effort will accelerate development of novel therapies for underserved diseases involving the central nervous system.
SAINT PAUL, MINN. – Minnetronix Neuro, a division of Minnetronix Medical, today announced that it has co-founded The Neurapheresis Consortium with Duke University. Designed to bring together leading researchers and clinicians, the consortium will accelerate the advancement of Neurapheresis Therapy, intended to improve outcomes for multiple, underserved patient populations, suffering from diseases involving infectious, inflammatory and neurodegenerative agents in the central nervous system.
Working in partnership with disease experts across the globe, Nandan Lad, M.D., Associate Professor of Neurosurgery at Duke, will lead the consortium’s efforts to advance Neurapheresis Therapy through pre-clinical research, and ultimately into the clinic for multiple indications. Neurapheresis Therapy is built on a proprietary technology platform developed by Minnetronix Neuro that is designed to prevent secondary injury and enhance healing by removing disease causing agents from the cerebral spinal fluid.
“We are building an exceptional team of global disease and medical technology experts to advance our research and develop truly novel therapies,” said Lad. “The Neurapheresis Consortium will unite the world’s leading authorities on specific disease states, medical technology experts and organizations that support grant-based funding, to help us deliver meaningful solutions to patients suffering from debilitating and life-threatening neurological conditions.”
Minnetronix Neuro will bring significant product development expertise to the consortium. The company began building its portfolio following the acquisition of patented technology that it developed into the Neurapheresis Therapy. Aaron McCabe Ph.D., head of research and development for Minnetronix Neuro, will provide nearly twenty years of medtech industry experience to the consortium.
“Our goal is simple: To improve outcomes for neuro patients who currently have few, if any, treatment options,” said Matt Adams, Minnetronix Neuro General Manager. “The Neurapheresis Consortium represents a powerful force of knowledge, skill and determination that will help transform the very real needs of patients suffering from neurological disease into life-enhancing solutions.”
About Neurapheresis Therapy
Neurapheresis Therapy is a platform technology in a portfolio of proprietary solutions being developed by Minnetronix Neuro for the Neuro ICU. During this minimally invasive process, a dual lumen catheter is placed in the lumbar spine, and contaminated CSF is actively filtered to rapidly remove blood and blood breakdown byproducts. Clean CSF is simultaneously returned to the patient. Neurapheresis Therapy is considered a breakthrough treatment option for aneurysmal subarachnoid hemorrhage patients, with the potential to significantly advance the current standard of care, improve outcomes for patients and minimize the impact of aSAH on the healthcare system. Neurapheresis Therapy is an investigational device, limited by Federal law to investigational use. More information about Neurapheresis Therapy and the Neurapheresis Consortium is available at www.neurapheresis.org
About Minnetronix Neuro
Minnetronix Neuro, a division of Minnetronix Medical, is developing a portfolio of solutions designed to prevent secondary injury and enhance healing for patients in the Neuro ICU. The company is focused on delivering cost-effective solutions for physicians and patients to advance treatment options and improve outcomes. www.minnetronixmedical.com